MX2015011846A - Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades. - Google Patents

Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades.

Info

Publication number
MX2015011846A
MX2015011846A MX2015011846A MX2015011846A MX2015011846A MX 2015011846 A MX2015011846 A MX 2015011846A MX 2015011846 A MX2015011846 A MX 2015011846A MX 2015011846 A MX2015011846 A MX 2015011846A MX 2015011846 A MX2015011846 A MX 2015011846A
Authority
MX
Mexico
Prior art keywords
methods
mis protein
subject
another aspect
treatment
Prior art date
Application number
MX2015011846A
Other languages
English (en)
Inventor
K Donahoe Patricia
Vavvas Demetrios
Pepin David
Van Hoang Mien
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of MX2015011846A publication Critical patent/MX2015011846A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se relaciona a proteína MIS humana recombinante modificada que tiene segmentación mejorada y bioactividad incrementada y potencia incrementada como se compara con la proteína MIS humana de tipo silvestre. Otros aspectos de la invención se relacionan a métodos para prevenir y tratar cánceres, tales como cánceres que expresan el receptor de MIS tipo II (MISRII) al administrar a un sujeto una composición que comprende una proteína MIS humana recombinante. Otro aspecto de la presente invención se relaciona a métodos para disminuir los niveles de andrógeno en el plasma en un sujeto, y/o para el tratamiento de un sujeto con una enfermedad caracterizada por andrógeno en exceso. Otro aspecto proporciona composiciones farmacéuticas y kits y métodos para uso, que comprenden una proteína MIS humana recombinante. Otro aspecto de la presente invención se relaciona a métodos para disminuir la dosis de un agente quimioterapéutico al administrar el agente quimioterapéutico con la proteína MIS recombinante que disminuye la dosis efectiva del agente quimioterapéutico.
MX2015011846A 2013-03-12 2014-03-12 Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades. MX2015011846A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361777135P 2013-03-12 2013-03-12
PCT/US2014/024010 WO2014164981A1 (en) 2013-03-12 2014-03-12 Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
MX2015011846A true MX2015011846A (es) 2016-09-27

Family

ID=51659030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011846A MX2015011846A (es) 2013-03-12 2014-03-12 Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades.

Country Status (14)

Country Link
US (2) US11084860B2 (es)
EP (1) EP2968470B1 (es)
JP (3) JP6698015B2 (es)
KR (1) KR20160029731A (es)
CN (1) CN105473154A (es)
AU (1) AU2014248768A1 (es)
BR (1) BR112015022181A8 (es)
CA (1) CA2904978A1 (es)
DK (1) DK2968470T3 (es)
ES (1) ES2853935T3 (es)
HK (1) HK1222331A1 (es)
MX (1) MX2015011846A (es)
PL (1) PL2968470T3 (es)
WO (1) WO2014164981A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968470B1 (en) * 2013-03-12 2020-10-28 The General Hospital Corporation Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases
US10258668B2 (en) 2013-09-20 2019-04-16 The General Hospital Corporation Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein
DK3079712T3 (da) * 2013-12-11 2022-04-25 Massachusetts Gen Hospital Anvendelse af müllersk inhiberende substans- (mis) proteiner til kontraception og ovariereservebevarelse
MA41629A (fr) * 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
WO2018112168A1 (en) * 2016-12-14 2018-06-21 The General Hospital Corporation Mullerian inhibiting substance (mis) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
CN107523586B (zh) * 2017-10-20 2020-03-17 广州万孚生物技术股份有限公司 免疫质粒及用于检测抗穆勒氏管激素的单抗、杂交瘤细胞及其制备方法和应用
WO2020044298A1 (en) * 2018-08-30 2020-03-05 Preglem Sa A novel use of the anti-müllerian hormone
AU2020282359A1 (en) 2019-05-31 2022-01-06 Laura DETTI Anti-Mullerian hormone receptor binding peptides
CN112251444B (zh) * 2020-10-21 2023-05-16 恺佧生物科技(上海)有限公司 一种改造的amh基因序列及利用其制备amh的方法
RU2770003C1 (ru) * 2021-04-05 2022-04-14 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Моноклональное антитело к С-концевому фрагменту антимюллерова гормона
CN115554403B (zh) * 2022-08-16 2024-03-08 山东大学 类固醇激素dhea作为受体adgrg2激动剂配体的应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447A (en) 1846-04-04 Car- wheel
US224A (en) 1837-06-03 Improvement in cotton-presses
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308483D0 (en) 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
ATE78515T1 (de) 1984-10-05 1992-08-15 Genentech Inc Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung.
US4963495A (en) 1984-10-05 1990-10-16 Genentech, Inc. Secretion of heterologous proteins
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
US5427780A (en) 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
EP0437427A4 (en) 1985-10-30 1992-07-01 Biogen, Inc. Cleaved dimers of mullerian inhibiting substance-like polypeptides
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5010055A (en) 1986-06-24 1991-04-23 The General Hospital Corporation Use of EGF to reverse the contraceptive activity of MIS
US4753794A (en) 1986-06-24 1988-06-28 The General Hospital Corporation Use of mullerian inhibiting substance as a contraceptive agent
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
GB8723662D0 (en) 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
US5061641A (en) 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5057301A (en) 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
EP0422049A4 (en) 1988-05-09 1991-11-13 Us Health Vector for secretion of proteins directly into periplasm or culture medium
US5759802A (en) 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
JPH02117384A (ja) * 1988-10-26 1990-05-01 Tonen Corp 酵母宿主によるヒト血清アルブミンａの製造
US5661126A (en) 1989-01-19 1997-08-26 The General Hospital Corporation Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5641671A (en) 1990-07-06 1997-06-24 Unilever Patent Holdings B.V. Production of active Pseudomonas glumae lipase in homologous or heterologous hosts
WO1992013951A1 (en) 1991-02-04 1992-08-20 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of human serum albumin in methylotrophic yeast cells
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
AU667578B2 (en) 1992-08-27 1996-03-28 Deakin Research Limited Retro-, inverso-, and retro-inverso synthetic peptide analogues
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
WO1994023697A1 (en) 1993-04-22 1994-10-27 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
CA2176712C (en) 1993-11-16 2000-05-23 Mantripragada Sankaram Synthetic membrane vesicles with controlled release of encapsulated biologically active substances
US5665557A (en) 1994-11-14 1997-09-09 Systemix, Inc. Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
US6495357B1 (en) 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
EP0857217B1 (en) 1995-10-16 2005-04-13 Dana-Farber Cancer Institute Novel expression vectors and methods of use
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
ES2257771T3 (es) 1996-10-28 2006-08-01 Amersham Health As Agentes de contraste.
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6361989B1 (en) 1997-10-13 2002-03-26 Novozymes A/S α-amylase and α-amylase variants
US6156552A (en) 1998-02-18 2000-12-05 Novo Nordisk A/S Lipase variants
US6428978B1 (en) * 1998-05-08 2002-08-06 Cohesion Technologies, Inc. Methods for the production of gelatin and full-length triple helical collagen in recombinant cells
US6323007B1 (en) 1998-09-18 2001-11-27 Novozymes A/S 2,6-β-D-fructan hydrolase enzyme and processes for using the enzyme
JP3711326B2 (ja) 1998-10-28 2005-11-02 ジェネンテック・インコーポレーテッド 細菌性細胞からの異種ポリペプチドの回収方法
WO2000058445A1 (en) 1999-03-29 2000-10-05 Novozymes A/S Polypeptides having branching enzyme activity and nucleic acids encoding same
EP1074265A1 (en) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
US6558939B1 (en) 1999-08-31 2003-05-06 Novozymes, A/S Proteases and variants thereof
EP1218025A4 (en) * 1999-09-14 2005-06-01 Gen Hospital Corp USE OF MULLER CHANNEL INHIBITION SUBSTANCE FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS CHARACTERIZED BY EXCESS ANDROGENES
US6673352B1 (en) 1999-09-14 2004-01-06 The General Hospital Corporation Use of Mullerian inhibiting substance for treating excess androgen states
DE19944870A1 (de) 1999-09-18 2001-03-29 Aventis Pharma Gmbh Signalsequenzen zur Herstellung von Leu-Hirudin über Sekretion durch E. coli in das Kulturmedium
US6617143B1 (en) 1999-10-20 2003-09-09 Novozymes A/S Polypeptides having glucanotransferase activity and nucleic acids encoding same
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US6509181B1 (en) 2000-04-14 2003-01-21 Novozymes, A/S Polypeptides having haloperoxide activity
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
NZ547233A (en) 2001-08-20 2008-11-28 Gen Hospital Corp Mullerian inhibiting substance levels and ovarian response
EP2277889B1 (en) * 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JP4809227B2 (ja) * 2003-09-26 2011-11-09 メルク セローノ ソシエテ アノニム タンパク質の産生に使用するためのリーダー配列
JP2008531059A (ja) 2005-03-04 2008-08-14 バイオレクシス ファーマシューティカル コーポレーション 改変トランスフェリン融合タンパク質
AU2005211556A1 (en) 2005-03-24 2006-10-12 Otago Innovation Limited Method Of Modulation
CA2625600A1 (en) 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
WO2007049977A2 (en) 2005-10-26 2007-05-03 Otago Innovation Limited Method of modulation of mullerian inhibitory substance (mis) receptor for the treatment of neurodegenerative diseases.
KR101491867B1 (ko) 2007-01-31 2015-02-10 피페넥스 인크. 증가된 발현을 위한 박테리아 리더 서열
WO2008116161A2 (en) * 2007-03-22 2008-09-25 The General Hospital Corporation Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states
EP2190481B1 (en) * 2007-07-17 2014-12-24 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
CA2699916A1 (en) 2007-09-18 2009-08-06 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
FR2993926A1 (fr) 2012-07-24 2014-01-31 Vianney Rabhi Turbomoteur basse-pression a combustion interne et/ou externe
EP2968470B1 (en) * 2013-03-12 2020-10-28 The General Hospital Corporation Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases
US10258668B2 (en) 2013-09-20 2019-04-16 The General Hospital Corporation Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein
DK3079712T3 (da) 2013-12-11 2022-04-25 Massachusetts Gen Hospital Anvendelse af müllersk inhiberende substans- (mis) proteiner til kontraception og ovariereservebevarelse

Also Published As

Publication number Publication date
JP2022180637A (ja) 2022-12-06
DK2968470T3 (da) 2021-02-01
US20160039898A1 (en) 2016-02-11
EP2968470A1 (en) 2016-01-20
EP2968470A4 (en) 2016-10-12
US20220041677A1 (en) 2022-02-10
ES2853935T3 (es) 2021-09-20
US11084860B2 (en) 2021-08-10
BR112015022181A2 (pt) 2017-11-21
AU2014248768A1 (en) 2015-09-24
JP2020074789A (ja) 2020-05-21
EP2968470B1 (en) 2020-10-28
WO2014164981A1 (en) 2014-10-09
PL2968470T3 (pl) 2021-05-31
JP2016518325A (ja) 2016-06-23
JP6698015B2 (ja) 2020-05-27
HK1222331A1 (zh) 2017-06-30
KR20160029731A (ko) 2016-03-15
CN105473154A (zh) 2016-04-06
CA2904978A1 (en) 2014-10-09
BR112015022181A8 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
MX2015011846A (es) Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades.
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
EA201792501A1 (ru) Вакцины для лечения и профилактики рака
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
MX2017007321A (es) Terapias de combinacion.
IN2015KN00414A (es)
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
NZ719905A (en) Bicyclic heterocycle compounds and their uses in therapy
GEP201706734B (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
NZ727516A (en) Treatment of ocular neovascularization using a recombinant virus containing a nucleic acid encoding a vegf inhibitor
MY166014A (en) Combination therapy methods for treating proliferative diseases
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MX2017003211A (es) Anticuerpos anti-met y composiciones.
EA201690159A1 (ru) Способы и композиции для лечения рака
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
IN2014DN06920A (es)
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
BR112015022846A2 (pt) uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo
MX358598B (es) Partículas inmuno-moduladoras modificadas.
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis